USAN drug names under consideration

USAN Council's statement on the use of USAN as domain names is that a name published by the United States Adopted Names (USAN) Program in the USP Dictionary of USAN and International Nonproprietary Names, and on the United States Adopted Names website shall be the effective equivalent of an intellectual property right for the relevant entities.

Visit United States Adopted Names FAQ to learn more.

Comments or protests should be addressed to Stephanie Shubat, USAN program director, American Medical Association, 330 North Wabash Ave., Suite 39300, Chicago, Illinois 60611, or via email: USAN@ama-assn.org. 

In order to ensure your "under consideration" USAN domain name is available, you should consider purchasing the .com, .net and .org domain names of the USAN under consideration. The optimal time to do this is when you receive the letter from the USAN Program informing you of the USAN Council's naming decision.

The following names for the drugs described are "under consideration" by the USAN Council:

Abiprubart: Treatment of autoimmune diseases

Avenciquat: Treatment of clinically significant portal hypertension 

Bexicaserin: Treatment of seizures associated with developmental and epileptic encephalopathies (DEEs) 

Bexicaserin HCl: Treatment of seizures associated with developmental and epileptic encephalopathies (DEEs) 

Brengitecan: Antineoplastic

Izalontamab: Antineoplastic

Izalontamab brengitecan: Antineoplastic

Lonimecgene renparvovec: Treatment of patients with Rett Syndrome 

Luxdegalutamide: Treatment of metastatic castration-resistant prostate cancer (mCRPC) 

Navepegritide: Treatment of achondroplasia and other skeletal disorders

Nerandomilast: Treatment of progressive fibrosing interstitial lung diseases (PF-ILD), also known as progressive pulmonary fibrosis (PPF), including idiopathic pulmonary fibrosis (IPF)

Opemalirsen: Treatment of segmental glomerulosclerosis (FSGS) and chronic kidney disease (CKD) 

Opemalirsen sodium: Treatment of segmental glomerulosclerosis (FSGS) and chronic kidney disease (CKD) 

Osavampator: Treatment of major depressive disorder

Pacibekitug: Treatment of inflammatory conditions mediated by interleukin 6 (IL-6) 

Pozetaldogene ormesparvovec: Treatment of adrenoleucodystrophy

Resiquimod sulfate: Antineoplastic

Ripasudil: Treatment of Fuchs endothelial corneal dystrophy

Ripasudil HCl: Treatment of Fuchs endothelial corneal dystrophy

Saroglitazar: Treatment of primary biliary cholangitis (PBC), Non-alcoholic steatohepatitis (NASH) and Nonalcoholic fatty liver disease in women with polycystic ovary syndrome (PCOS)

Saroglitazar magnesium: Treatment of primary biliary cholangitis (PBC), Non-alcoholic steatohepatitis (NASH) and Nonalcoholic fatty liver disease in women with polycystic ovary syndrome (PCOS)

Sipavibart: Treatment of severe acute respiratory syndrome (SARS) and COVID-19

Tebapivat: Treatment of hemolytic anemias associated with sickle cell disease (SCD); and other hematopoietic disorders, like anemia associated with myelodysplastic syndrome (MDS) 

Zanidatamab: Antineoplastic

Zevotrelvir: Treatment of COVID-19 

Cemacabtagene ansegedleucel: Antineoplastic; cell-based gene therapy

Cibotercept: Treatment of pulmonary arterial hypertension (PAH) and bone diseases, including osteoporosis and osteogenesis imperfecta (OI)

Dargistotug: Antineoplastic

Edelinontrine: Treatment of heart failure (HF); previously investigated for the treatment of patients with Alzheimer’s disease and sickle cell disease 

Firicabtagene autoleucel: Antineoplastic; cell-based gene therapy

Icalcaprant: Treatment of major depressive disorder (MDD)

Imdatifan: Treatment of clear renal cell carcinoma (ccRCC)

Lartesertib: Antineoplastic

Leramistat: Treatment of rheumatoid arthritis (RA) and other autoimmune conditions

Londamocitinib: Treatment of asthma and respiratory diseases

Londamocitinib xinofoate: Treatment of asthma and respiratory diseases

Mivelsiran: Treatment of Alzheimer’s disease and cerebral amyloid angiopathy

Mivelsiran sodium: Treatment of Alzheimer’s disease and cerebral amyloid angiopathy

Nedometinib: Treatment of cutaneous neurofibromas (cNF) in patients with neurofibromatosis type 1(NF1)

Nilotinib D-tartrate: Antineoplastic

Nilotinib tartaric acid: Antineoplastic

Onvapegleukin alfa: Antineoplastic

Orziloben: Treatment of intestinal failure associated with liver disease (IFALD)

Quabodepistat: Treatment of tuberculosis

Sigvotatug: Antineoplastic

Sigvotatug vedotin: Antineoplastic

Varegacestat: Antineoplastic

Vilastobart: Antineoplastic

Visugromab: Antineoplastic

Zegocractin: Treatment of acute inflammatory and immunologic diseases

Miafilcon A: Contact lens material

Miafilcon B: Contact lens material

Artenimol: Antimalarial

Courfilcon A: Contact lens material

Diazoxide choline: Antineoplastic

Disitamab: Antineoplastic

Disitamab vedotin: Antineoplastic

Dorocubicel: Hematopoietic stem cell transplantation; Cellular immunotherapy for treatment of cancer

Efzimfotase alfa: Enzyme replacement therapy (ERT) to address the underlying cause of hypophosphatasia (HPP)

Empasiprubart: Treatment of complement mediated diseases

Etentamig: Antineoplastic

Frevecitinib: Treatment of asthma and chronic obstructive pulmonary disease (COPD)

Fulipiftide: Treatment of Ophthalmic diseases such as dry eye disease (DED)

Idroxioleic acid: Antineoplastic

Idroxioleate sodium: Antineoplastic

Levacetylleucine: Treatment of neurodegenerative disorders, including Niemann-Pick disease type C (NPC), GM2 gangliosidosis, GM1 gangliosidosis and ataxia-telangiectasia (A-T)

Lucicebtide: Antineoplastic

Macupatide: Antihyperglycemic

Pamirtecan: Antineoplastic

Pemivibart: Prevention and treatment of COVID-19

Revifilcon A: Contact lens material

Sumecigrel: Antiplatelet agent

Trastuzumab pamirtecan: Antineoplastic

Verekitug: Treatment of asthma and inflammatory diseases

Vorbipiprant: Immunomodulator for tumors and autoimmune diseases

Vorpiprant sodium: Immunomodulator for tumors and autoimmune diseases

Votoplam: Treatment of Huntington’s disease